You are not currently logged in.
Access JSTOR through your library or other institution:
Use of Capsular Polysaccharide-Tetanus Toxoid Conjugate Vaccine for Type II Group B Streptococcus in Healthy Women
Carol J. Baker, Lawrence C. Paoletti, Marcia A. Rench, Hilde-Kari Guttormsen, Vincent J. Carey, Melissa E. Hickman and Dennis L. Kasper
The Journal of Infectious Diseases
Vol. 182, No. 4 (Oct., 2000), pp. 1129-1138
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30110088
Page Count: 10
You can always find the topics here!Topics: Vaccination, Conjugate vaccines, Antibodies, Polysaccharides, Immune response, Dosage, Infections, Immunization, Oxidation, Streptococcus agalactiae
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
An estimated 15% of invasive group B streptococcal (GBS) disease is caused by type II capsular polysaccharide (II CPS). In developing a pentavalent vaccine for the prevention of GBS infections, individual GBS CPSs have been coupled to tetanus toxoid (TT) to prepare vaccines with enhanced immunogenicity. Type II GBS (GBS II) vaccine was created by direct, covalent coupling of II CPS to TT by reductive amination. In 2 clinical trials, 75 healthy nonpregnant women 18-45 years old were randomized to receive II CPS-TT (II-TT) conjugate (dose range, 3.6-57 µg of CPS component) or uncoupled II CPS vaccine. Both vaccines were well tolerated. II CPS-specific IgG serum concentrations (as well as IgM and IgA) peaked 2 weeks after immunization, being significantly higher in recipients of conjugated vaccine than in recipients of uncoupled CPS. Immunological responses to conjugate were dose dependent and correlated with opsonophagocytosis in vitro. These results support inclusion of II-TT conjugate when preparing a multivalent GBS vaccine.
The Journal of Infectious Diseases © 2000 Oxford University Press